281 related articles for article (PubMed ID: 22314419)
1. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers.
Shen J; Chan HL; Wong GL; Choi PC; Chan AW; Chan HY; Chim AM; Yeung DK; Chan FK; Woo J; Yu J; Chu WC; Wong VW
J Hepatol; 2012 Jun; 56(6):1363-70. PubMed ID: 22314419
[TBL] [Abstract][Full Text] [Related]
2. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers.
Shen J; Chan HL; Wong GL; Chan AW; Choi PC; Chan HY; Chim AM; Yeung DK; Yu J; Chu WC; Wong VW
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1057-66. PubMed ID: 23066946
[TBL] [Abstract][Full Text] [Related]
3. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children.
Feldstein AE; Alkhouri N; De Vito R; Alisi A; Lopez R; Nobili V
Am J Gastroenterol; 2013 Sep; 108(9):1526-31. PubMed ID: 23752877
[TBL] [Abstract][Full Text] [Related]
4. Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis.
Yang M; Xu D; Liu Y; Guo X; Li W; Guo C; Zhang H; Gao Y; Mao Y; Zhao J
PLoS One; 2015; 10(6):e0131664. PubMed ID: 26121037
[TBL] [Abstract][Full Text] [Related]
5. [Clinical significance of the measurement of serum cytokeratin-18 in patients with non-alcoholic steatohepatitis].
Watanabe T; Takemura M; Saito K; Ito H; Hattori T; Sekine A; Yamada K; Kato T; Tomita E; Matsuoka T; Seishima M
Rinsho Byori; 2013 Jan; 61(1):19-24. PubMed ID: 23672077
[TBL] [Abstract][Full Text] [Related]
6. High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China.
Li H; Dong K; Fang Q; Hou X; Zhou M; Bao Y; Xiang K; Xu A; Jia W
J Hepatol; 2013 Mar; 58(3):557-63. PubMed ID: 23142063
[TBL] [Abstract][Full Text] [Related]
7. Apoptotic and anti-apoptotic seromarkers for assessment of disease severity of non-alcoholic steatohepatitis.
El Bassat H; Ziada DH; Hasby EA; Nagy H; Abo Ryia MH
Arab J Gastroenterol; 2014 Mar; 15(1):6-11. PubMed ID: 24630506
[TBL] [Abstract][Full Text] [Related]
8. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
9. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients.
Diab DL; Yerian L; Schauer P; Kashyap SR; Lopez R; Hazen SL; Feldstein AE
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1249-54. PubMed ID: 18995215
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease.
Lebensztejn DM; Wierzbicka A; Socha P; Pronicki M; Skiba E; Werpachowska I; Kaczmarski M
Acta Biochim Pol; 2011; 58(4):563-6. PubMed ID: 22140659
[TBL] [Abstract][Full Text] [Related]
11. Validation of the non-alcoholic fatty liver disease activity score.
Hjelkrem M; Stauch C; Shaw J; Harrison SA
Aliment Pharmacol Ther; 2011 Jul; 34(2):214-8. PubMed ID: 21585409
[TBL] [Abstract][Full Text] [Related]
12. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.
Wieckowska A; Zein NN; Yerian LM; Lopez AR; McCullough AJ; Feldstein AE
Hepatology; 2006 Jul; 44(1):27-33. PubMed ID: 16799979
[TBL] [Abstract][Full Text] [Related]
13. Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease.
Kawanaka M; Nishino K; Nakamura J; Urata N; Oka T; Goto D; Suehiro M; Kawamoto H; Yamada G
Ann Hepatol; 2015; 14(6):837-44. PubMed ID: 26436355
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride.
Li H; Fang Q; Gao F; Fan J; Zhou J; Wang X; Zhang H; Pan X; Bao Y; Xiang K; Xu A; Jia W
J Hepatol; 2010 Nov; 53(5):934-40. PubMed ID: 20675007
[TBL] [Abstract][Full Text] [Related]
15. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
Ito S; Yukawa T; Uetake S; Yamauchi M
Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.
Feldstein AE; Wieckowska A; Lopez AR; Liu YC; Zein NN; McCullough AJ
Hepatology; 2009 Oct; 50(4):1072-8. PubMed ID: 19585618
[TBL] [Abstract][Full Text] [Related]
17. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.
Wong VW; Wong GL; Choi PC; Chan AW; Li MK; Chan HY; Chim AM; Yu J; Sung JJ; Chan HL
Gut; 2010 Jul; 59(7):969-74. PubMed ID: 20581244
[TBL] [Abstract][Full Text] [Related]
18. Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic Fatty liver disease.
Papatheodoridis GV; Hadziyannis E; Tsochatzis E; Georgiou A; Kafiri G; Tiniakos DG; Margariti K; Manolakopoulos S; Manesis EK; Archimandritis AJ
J Clin Gastroenterol; 2010 Apr; 44(4):e87-95. PubMed ID: 19881359
[TBL] [Abstract][Full Text] [Related]
19. A novel pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis.
Grigorescu M; Crisan D; Radu C; Grigorescu MD; Sparchez Z; Serban A
J Physiol Pharmacol; 2012 Aug; 63(4):347-53. PubMed ID: 23070083
[TBL] [Abstract][Full Text] [Related]
20. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease.
Palekar NA; Naus R; Larson SP; Ward J; Harrison SA
Liver Int; 2006 Mar; 26(2):151-6. PubMed ID: 16448452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
